Condition: Squamous Cell Carcinoma · Sponsor: Stanford University
The study objective is to see if BVEC induced C7 expression in Recessive Dystrophic Epidermolysis Bullosa (RDEB) skin following Squamous cell carcinoma (SCC) excision will normalize the invasive tumor microenvironment and reduce tumor recurrence. Prevention of SCC's in the RDEB subjects will increase their life span.
This description comes directly from the study's public registry record.
Kunju Sridhar · 650-721-4902 · kunju@stanford.edu
Always discuss trial participation with your own doctor first.
| Stanford University | Redwood City, California, United States | Recruiting |
| Azienda Ospedliero-Universitaia | Bari, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06731933